Philippinen - Englisch - FDA (Food And Drug Administration)

n/a; importer: n/a; distributor: starpharm, inc. - ascorbic acid , zinc - tablet - 500 mg (equivalent to 562.5 mg sodium ascorbate)/ 10 mg (equivalent 27.5 mg zinc sulfate monohydrate)

Philippinen - Englisch - FDA (Food And Drug Administration)

starpharm inc. - ascorbic acid , zinc - syrup - 100mg/ 10mg per 5ml

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

austarpharma llc - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. 2. generalized tonic-clonic seizures (grand mal). 3. mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. likewise, on theoretical grounds its use with monoamine oxidase (mao) inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.

Singapur - Englisch - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - obstetrics & gynaecology - betadine™ bv gel is a clear gel intended to be applied into the vagina and has been clinically tested to shown to • treat bacterial vaginosis (bv), restore vaginal flora balance and normalize vaginal ph. • provide rapid resolution of symptoms including fishy vaginal odour and discharge. • prevent recurrent bv and its symptoms.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

austarpharma llc - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil tablets is indicated for the treatment of erectile dysfunction. consistent with its known effects on the nitric oxide/cgmp pathway [see  clinical pharmacology (12.1,  12.2) ], sildenafil tablets was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. after patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see  dosage and administration (2.3),  drug interactions (7.1), and clinical pharmacology (12.2) ]. sildenafil tablets is contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil tablets and revatio, or any component of the tablet. hypersensitivity reactions have been reported, including rash and urticaria [see  adverse reactions (6.1) ]. do not use sildenafil tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including sildenafil tablets, may potentiate the hypotensive effects of gc stimulators. risk summary sildenafil tablets is not indicated for use in females. there are no data with the use of sildenafil tablets in pregnant women to inform any drug-associated risks for adverse developmental outcomes. animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (mrhd) of 100 mg/day on a mg/m2 basis (see data). data animal data no evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. these doses represent, respectively, about 16 and 32 times the mrhd on a mg/m2 basis in a 50 kg subject. in the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the mrhd on a mg/m2 basis in a 50 kg subject. risk summary sildenafil tablets is not indicated for use in females. limited data indicate that sildenafil and its active metabolite are present in human milk. there is no information on the effects on the breastfed child, or the effects on milk production. sildenafil tablets is not indicated for use in pediatric patients. safety and effectiveness have not been established in pediatric patients. healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma auc values of sildenafil and its active n-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18–45 years) [see  clinical pharmacology (12.3) ]. due to age-differences in plasma protein binding, the corresponding increase in the auc of free (unbound) sildenafil and its active n-desmethyl metabolite were 45% and 57%, respectively [see  clinical pharmacology (12.3) ]. of the total number of subjects in clinical studies of viagra, 18% were 65 years and older, while 2% were 75 years and older. no overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects. however, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure [see dosage and administration (2.5) ]. no dose adjustment is required for mild (clcr=50–80 ml/min) and moderate (clcr=30–49 ml/min) renal impairment. in volunteers with severe renal impairment (clcr<30 ml/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of cmax and auc. a starting dose of 25 mg should be considered in patients with severe renal impairment [ see dosage and administration (2.5) and  clinical pharmacology (12.3) ]. in volunteers with hepatic impairment (child-pugh class a and b), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for cmax and 85% for auc). the pharmacokinetics of sildenafil in patients with severely impaired hepatic function (child-pugh class c) have not been studied. a starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see dosage and administration (2.5)  and  clinical pharmacology (12.3) ].

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

starpharma pty ltd - 47601 - vaginal flora gel - astodrimer sodium (fleurstat; vivagel?), in the form of a gel applied by the user into the vagina: once daily for seven days, for topical treatment and rapid relief of bacterial vaginosis (bv), including unpleasant vaginal odour and discharge, helping to normalise vaginal ph and restore the normal vaginal flora balance; once every second day, for prevention of recurrent bv, including prevention of unpleasant vaginal odour and discharge, helping to maintain normal vaginal ph and vaginal flora balance. after application, the device cannot be reused.

Philippinen - Englisch - FDA (Food And Drug Administration)

starpharm, inc - buclizine hydrochloride , vitamin b-complex , iron (see reverse for formulation) - syrup - each 5 ml contains: buclizine hydrochloride thiamine hydrochloride (vit. bi) pyridoxine hydrochloride (vit. b6) cyanocobalamin (vit. b12) ferrous sulfate (eq. to 10 mg elemental iron) 5 mg 10 mg

Philippinen - Englisch - FDA (Food And Drug Administration)

starpharm, inc. - guaifenesin , salbutamol (as sulfate) - syrup - 5mg/ 10mg per 5ml

Philippinen - Englisch - FDA (Food And Drug Administration)

starpharm inc - mefenamic acid - suspension, oral - 50mg/5ml

Philippinen - Englisch - FDA (Food And Drug Administration)

starpharm, inc. - phenylephrine hydrochloride , brompheniramine maleate - syrup (oral drops) - 2.5mg/ 1mg per ml